Volume 30, Number 11—November 2024
Synopsis
Mortality Rates after Tuberculosis Treatment, Georgia, USA, 2008–2019
Sarah Gorvetzian1, Antonio G. Pacheco, Erin Anderson, Susan M. Ray, and Marcos C. Schechter
Table 2
TB diagnosis and treatment characteristics stratified according to posttreatment death, HIV infection, and place of birth in study of mortality rates after TB treatment, Georgia, USA, 2008–2019*
| Characteristics | No. (%) patients |
|||
|---|---|---|---|---|
| Overall cohort | Posttreatment deaths | HIV positive | US-born persons | |
| Total no. patients |
3,218 |
233 |
328 |
1,557 |
| Case verification | ||||
| Culture confirmed | 2,391 (75) | 190 (8) | 243 (10) | 1,213 (51) |
| Clinical case | 743 (23) | 39 (5) | 83 (11) | 327 (44) |
| Other† |
48 (2) |
4 (8) |
2 (4) |
17 (35) |
| Site of TB disease | ||||
| Pulmonary | 2,551 (80) | 202 (8) | 270 (11) | 1,306 (51) |
| Extrapulmonary TB |
631 (20) |
31 (5) |
58 (9) |
251 (40) |
| Cavitary disease, n = 2,551 patients with pulmonary disease‡ | ||||
| No | 1,513 (59) | 116(8) | 214 (14) | 729 (48) |
| Yes |
1,038 (41) |
86 (8) |
56 (5) |
577 (56) |
| Sputum smear, n = 2,551 patients with pulmonary disease‡ | ||||
| Negative | 1,254 (49) | 95 (8) | 137 (11) | 650 (52) |
| Positive | 1,192 (47) | 98 (8) | 124 (10) | 600 (50) |
| Missing data |
105 (4) |
9 (9) |
9 (9) |
56 (53) |
| Drug susceptibility, n = 2,357 patients with available results‡ | ||||
| RIF/INH susceptible | 2,077 (88) | 167 (8) | 189 (9) | 1,029 (50) |
| RIF susceptible/INH resistant | 250 (11) | 20 (8) | 50 (20) | 158 (63) |
| RIF resistant |
30 (1) |
1 (3) |
3 (10) |
10 (33) |
| Completed tuberculosis treatment | ||||
| Yes | 2,973 (93) | 218 (7) | 303 (10) | 1,514 (51) |
| No | 211 (7)§ | 15 (7) | 25 (12) | 43 (21) |
*INH, isoniazid; RIF, rifampin; TB, tuberculosis. †Other comprised positive smear/tissue (n = 6) and positive nucleic acid amplification (n = 42). ‡Number of patients used in denominator to calculate percentage in overall cohort column. §Incomplete treatment included adverse treatment events (n = 11), uncooperative or refused treatments (n = 12), lost to follow-up (n = 87), moved out of jurisdiction (n = 6), or reason was missing (n = 95).
1Current affiliation: University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Page created: September 12, 2024
Page updated: October 22, 2024
Page reviewed: October 22, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.